menu

Press Release Details

All Press Releases

Top US Government Agency Validates Benefits of Croslite™ Material

July 17, 2008

Media Contact:

Shelley Forslund

Crocs Footwear

303-848-7197

sforslund@crocs.com

Elexis Lewis

Linhart Public Relations

303-951-2557

elewis@linhartpr.com

Top US Government Agency Validates Benefits of Croslite™ Material

The CrocsRX™ Custom Cloud Model is First Molded Shoe Approved by Centers for Medicare and Medicaid Services

Niwot , Colo. , July 17, 2008 – Today, CrocsRx ™, the medical division of Crocs, Inc. (NASDAQ: CROX), announced the Center for Medicare and Medicaid Services (CMS) has accepted the Custom Cloud model into the diabetic shoe program. Acceptance by the CMS validates the superior benefits of Croslite™ material, Crocs proprietary closed-cell resin, as the Custom Cloud is the first molded shoe to receive an approved code verification from the organization.

Effective immediately, medical professionals can fit the more than 23 million Americans suffering from diabetes in the CrocsRx™ Custom Cloud. The approved shoe comes with three pairs of heat moldable orthotic insoles and is fitted by a professional practitioner, to offer long-term relief for foot ailments related to the disease.

Recognized by the American Podiatric Medical Association with its distinguished Seal of Acceptance, the Custom Cloud offers diabetic patients several advantages over traditional specialty footwear. Among the most notable benefit is the customized fit that stems from the Croslite Ag+™ material. Croslite Ag+™ material expands upon the comfort attributes inherent to Croslite™ material while adding anti-bacterial, anti-fungal and odor resistant nano-Silver ceramic crystals. Moreover, patients find the Custom Cloud to be easier to slip on, easier to keep clean and that the shoe weighs less than other specialty medical footwear styles accepted by CMS. The Custom Cloud is available in three color combinations including Navy, Black and Chocolate in men’s size 4-13.5 and women’s size 6-13.5, with four width offerings.

“We are thrilled with the Center for Medicare and Medicaid’s decision to include CrocsRx™ footwear in the Medicare program,” stated Eddie Scott, Director of CrocsRx™.  “CMS acceptance is an enormous accomplishment as this governing body completed an extensive review of clinical and historical performance data and found Croslite™ material to be a suitable alternative to existing specialty leather footwear.”

To learn more about CrocsRx™ footwear, or join the more than 4,000 doctors that either recommend shoes from the CrocsRx™ line to their patients or distribute CrocsRx™ models directly through their offices, visit www.crocsrx.com.

About Crocs, Inc:
Crocs, Inc. is a rapidly growing designer, manufacturer and retailer of footwear for men, women and children under the Crocs™ brand.

All Crocs™ brand shoes feature Crocs’ proprietary closed-cell resin, Croslite™, which represents a substantial innovation in footwear. The Croslite™ material enables us to produce soft, comfortable, lightweight, superior-gripping, non-marking and odor-resistant shoes. These unique elements make Crocs™ footwear ideal for casual wear, as well as for professional and recreational uses such as boating, hiking, hospitality and gardening. The versatile use of the material has enabled us to successfully market our products to a broad range of consumers.

The first footwear brand to receive the prestigious APMA Executive Director’s award and Company of the Year award from the Student Association of the APMA in a single year, CrocsRX™ is a leader in medical shoe sales with more than 3,000 doctors recommending or distributing the brand to patients. CrocsRX™ shoes are made from Crocs’ proprietary Croslite™ material and are designed to alleviate pain and discomfort from a variety of health related ailments. For more information, visit www.crocsrx.com.


Crocs™ shoes are sold in more than 90 countries and come in a wide array of colors and styles. Please visit www.crocs.com for additional information.

Categories: Press Releases
All Press Releases